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Background:  Many  large-scale  clinical  trials  have  conﬁrmed  that  statins  are  effective  in reducing  low-
density  lipoprotein  cholesterol  (LDL-C)  level,  resulting  in  reducing  cardiovascular  events.  Recent  studies
have  focused  on the effects  of  statins  on  high-density  lipoprotein  cholesterol  (HDL-C).  Here we compared
the  effects  of  two statins  on lipid  proﬁle  and  other metabolic  parameters.
Methods: The  study population  included  129  patients  with  stable  coronary  artery  disease,  hyper-
cholesterolemia,  and  hypo-HDL-cholesterolemia  (HDL-C  <  50 mg/dl).  They  were  randomly  allocated  to
treatment  by pitavastatin  2–4  mg/day  or atorvastatin  10–20  mg/day  and followed-up  for  30  months.
The  primary  endpoint  was  percent  changes  in HDL-C  and  adiponectin  during  the  study.  The  secondary
endpoints  were  percent  and  absolute  changes  in  markers  of  glucose  metabolism,  serum  lipids,  and
apolipoproteins.
Results:  The  effects  of  30-month  treatment  with  pitavastatin  on  HDL-C  were  signiﬁcantly  greater  than
those  of  atorvastatin  (%change:  pitavastatin:  20.1  ±  25.7%,  atorvastatin:  6.3 ±  19.8%, p =  0.01;  absolute
change:  pitavastatin:  7.3  ±  9.1  mg/dl,  atorvastatin:  2.3 ±  8.0  mg/dl,  p =  0.02).  A similar  trend  was  seen
with  regard  to apolipoprotein-AI  (ApoAI)  (%change:  pitavastatin:  20.8  ± 19.3%,  atorvastatin:  11.4  ±  17.6%,
p  =  0.03;  absolute  change:  pitavastatin:  23.1  ±  20.2  mg/dl,  atorvastatin:  12.1  ±  19.4  mg/dl,  p  =  0.02).  Treat-
ment  with  pitavastatin,  but not  atorvastatin,  signiﬁcantly  increased  adiponectin  levels. Neither  statin  had
a  signiﬁcant  effect  on hemoglobin  A1c.  No severe  adverse  events  were  registered  during  the  study.
Conclusion: Long-term  treatment  with  pitavastatin  resulted  in signiﬁcantly  greater  increases  in serum
HDL-C  and  ApoAI  levels  without  adverse  effects  on  glucose  metabolism,  compared  with  atorvastatin.
© 2013  Published  by  Elsevier  Ltd on  behalf  of Japanese  College  of Cardiology.ntroduction
Several large-scale clinical trials have shown that 3-hydroxy-
-methyl-glutaryl co-enzyme A reductase inhibitors (statins) are
ffective in reducing low-density lipoprotein cholesterol (LDL-C)
evels, resulting in a signiﬁcant reduction in cardiovascular events
1–3]. Furthermore, aggressive lipid-lowering treatment with ator-
astatin resulted in a greater reduction in the progression of
∗ Corresponding author at: 1-1-1 Honjo, Chuo-Ku, Kumamoto City 860-8556,
umamoto,  Japan. Tel.: +81 96 373 5175; fax: +81 96 362 3256.
E-mail  address: ssugiyam@kumamoto-u.ac.jp (S. Sugiyama).
914-5087/$ – see front matter © 2013 Published by Elsevier Ltd on behalf of Japanese Co
ttp://dx.doi.org/10.1016/j.jjcc.2013.03.008coronary atherosclerosis and prevention of cardiovascular events
than moderate treatment with pravastatin [4]. In this regard, ele-
vated LDL-C is considered the primary target of lipid-lowering
therapy, and the concept of “the lower, the better” in LDL-C is
widely recognized in Western countries. In the post hoc analy-
sis of the “Treating to New Targets (TNT)” study, despite strict
control of LDL-C (LDL-C < 70 mg/dl) with statins, the risk of car-
diovascular events remained high in patients with low levels of
high-density lipoprotein cholesterol (HDL-C) [5]. In this regard,
HDL-C plays an important role in atherosclerosis based on its anti-
atherosclerotic properties, and recent research has strongly focused
on improvement in HDL-C level as a residual risk for prevention of
cardiovascular events in the era of statin-treatment.
llege of Cardiology.
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Pitavastatin is a strong statin and commonly used in Japan. It
educes cholesterol synthesis in the liver through competitive and
ffective inhibition of 3-hydroxy-3-methyl-glutaryl co-enzyme A
eductase. It also induces the expression of LDL-C receptors, result-
ng in increased hepatic uptake of LDL-C from the circulation [6]. On
he other hand, pitavastatin increases serum levels of HDL-C [7,8]
lthough it does not have harmful effects on glucose tolerance [9].
ecent reports have shown that pitavastatin has pleiotropic effects.
The use of pitavastatin is reported to produce signiﬁcant
egression of coronary plaques in patients with acute coronary
yndrome [10,11]. In one study of patients with hyper-LDL-
holesterolemia and glucose intolerance, 52-week treatment with
itavastatin was  associated with signiﬁcantly greater increases
n HDL-C and apolipoprotein AI (ApoAI) levels than atorvastatin
12]. To our knowledge, however, the precise differences between
hese two statins with regard to their effects on HDL-C lev-
ls, glucose metabolism, and adiponectin levels in very high-risk
atients with stable coronary artery disease (CAD) and hypo-HDL-
holesterolemia have not been determined. The present study
ompared the outcome of 30-month treatment with pitavastatin
nd atorvastatin on changes in HDL-C, adiponectin, and other
etabolic parameters, in patients with stable CAD, hypercholes-
erolemia, and hypo-HDL-cholesterolemia.
ethods
atient  population
Eligible patients were men  and women, aged 20–85 years,
ith clinically evident stable CAD, which was deﬁned by one
r more of the following: previous myocardial infarction, pre-
ious or current angina with objective evidence of obstructive
therosclerotic CAD (≥75% stenosis in major coronary arter-
es), and history of coronary revascularization including coronary
rtery bypass grafting (CABG). Eligible criteria were serum HDL-
 < 50 mg/dl and LDL-C > 100 mg/dl under statin treatment or
DL-C > 140 mg/dl without lipid-lowering medications at random-
zation. Unstable patients with acute myocardial infarction (AMI)
ithin three months after onset, and coronary intervention includ-
ng CABG within one month were excluded. The exclusion criteria
ncluded allergy to pitavastatin or atorvastatin, familial hyper-
holesterolemia, severe hypertension (systolic blood pressure
180 mmHg  or diastolic blood pressure >110 mmHg), renal dis-
rders (serum creatinine > 1.5 mg/dl) or current dialysis, family
istory of hypothyroidism or muscular dystrophy, history of drug-
nduced hepatic disorder, drug abuse or dipsomania, cardiogenic
hock, and females who were pregnant or who planned to become
regnant during this study.
thics statement
This  study was conducted in accordance with the Declaration of
elsinki established by the World Medical Association and ‘Ethical
rinciples in Clinical Studies’ published by the Ministry of Health,
abor and Welfare of Japan, and following the approval of the
nstitutional review board of Kumamoto University and each par-
icipating institution. The study protocol was explained to patients
ho met  the criteria for inclusion and written informed consent
as obtained from the participants.
tudy designComparison of pitavastatin with atorvastatin in increasing HDL-
holesterol and adiponectin in patients with dyslipidemia and
oronary artery disease (COMPACT-CAD) was a 30-month random-
zed, non-blinded, multicenter study of patients with stable CAD.iology 62 (2013) 87–94
Enrollment  and randomization were carried out from September
2008 to September 2009. Eligible patients were randomized (1:1)
to receive pitavastatin (2–4 mg) or atorvastatin (10–20 mg) once
daily for 30 months. Factors used for allocation were LDL-C level,
sex, having diabetes mellitus (DM) or not, and prior statin usage.
Throughout the study, the attending physician was free to change
the dose of statins to achieve lipid control (LDL-C < 70 mg/dl). The
effects of the two statins on the primary and secondary endpoints
were assessed at baseline, and at 6, 12, and 30 months later.
Primary  and secondary endpoints
The primary endpoint was  the percent changes in HDL-C and
adiponectin levels at 30 months relative to the baseline values. The
secondary endpoints included (1) absolute and percent changes in
glucose metabolism markers: fasting glucose, and HbA1c; (2) abso-
lute change in adiponectin; (3) absolute and percent changes in
serum lipids and apolipoproteins [total cholesterol, LDL-C, triglyc-
eride, HDL-C, non-HDL-C, LDL-C/HDL-C, ApoAI, ApoB, ApoB/ApoAI];
(4) death and any adverse cardiac events; and (5) adverse effects
including changes in laboratory data.
Laboratory measurements
Peripheral  blood samples were obtained after a 12-h overnight
fast at baseline and after 6, 12, and 30 months of treatment. Serum
was separated by centrifugation at 3000 rpm at 10 ◦C for 10 min
and stored at −20 ◦C then transferred to the central laboratory
(SRL Inc., Tokyo, Japan). Serum HDL-C concentration was deter-
mined by direct method using cholesterol oxidase. Adiponectin
levels were measured using latex agglutination-turbidimetric
immunoassay. Total cholesterol levels were measured using
cholesterol dehydrogenase-UV method. Triglyceride levels were
measured using enzymatic method. LDL-C levels were measured
using direct method. ApoAI and ApoB were measured using turbidi-
metric immunoassay. Fasting glucose levels were measured using
the hexokinase-ultraviolet method. HbA1c values were determined
using latex agglutination-turbidimetric immunoassay.
Statistical analysis
The  Kolmogorov–Smirnov test was used to assess the distribu-
tion of continuous data. Normally distributed data were expressed
as mean ± standard deviation, whereas those with skewed distri-
bution were expressed as the median value with interquartile range
(IQR). Categorical data were presented as frequencies and percent-
ages. Differences between the two groups were tested with the
chi-square test for categorical variables. Differences in continuous
variables were analyzed by the unpaired t-test or Mann–Whitney
U-test, as appropriate. The Bonferroni corrected t-test was used to
analyze differences in the two groups at follow-up of 6, 12, and 30
months of treatment. Signiﬁcance levels of adjusted p-value at each
follow-up point were set at <0.05 at 6 months, <0.025 at 12 months,
and <0.017 at 30 months.
The  primary endpoints, percent changes in HDL-C and
adiponectin levels at 30 months, were analyzed by unpaired t-test.
The mean difference in percent change and the two-sided 95% con-
ﬁdence interval were calculated for the difference in drug effect
between the pitavastatin and atorvastatin groups, at baseline, and
at 6, 12, and 30 months later. The one-sample t-test was used to
assess the efﬁcacy of each drug at 6, 12, and 30 months of treatment.
The secondary endpoints were analyzed using the same approach.
The numbers of cardiovascular events and adverse events were
also assessed to determine the safety proﬁle. The total numbers
of side effects and adverse events were assessed and categorized
according to severity. Differences in treatments were evaluated by
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he intention to treat analysis and considered statistically signiﬁ-
ant at a p-value < 0.05 or under the Bonferroni adjusted p-value as
ppropriate. All statistical analyses were conducted using IBM SPSS
tatistics 20 (Chicago, IL, USA).
esults
atient characteristics
A  total of 129 patients were enrolled from September 2008 to
eptember 2009 in 17 hospitals in Japan. Of these, 65 patients were
ssigned to pitavastatin treatment and 64 patients were assigned
o atorvastatin treatment randomly. Before the end of 12 months
f treatment, 5 patients discontinued treatment because of adverse
vents, and 21 patients failed to return to the hospital after registra-
ion, and were considered to have withdrawn consent. At the end
f the 30-month treatment, 58 patients had ﬁnally failed to return
o the hospital. Thus, 71 patients were included in the effectiveness
nalysis. The mean dose of pitavastatin was 2.2 ± 0.6 mg/day while
hat of atorvastatin was 10.5 ± 2.1 mg/day.
Table 1 summarizes the baseline characteristics of the study
articipants. There were no signiﬁcant differences between the
wo groups in all the tested parameters. The majority of the
tudy patients were men  (81.4%), and the prevalence of dia-
etes mellitus was 40.3%. At the start of the study, 62.0% of
he patients were not receiving statin treatment. HDL-C levels
t baseline were 39.9 ± 6.5 mg/dl in the pitavastatin group and
0.1 ± 5.5 mg/dl in the atorvastatin group (p = 0.90). At baseline,
erum adiponectin level was 9.4 ± 7.1 g/ml in the pitavastatin
roup, and 9.5 ± 5.6 g/ml in the atorvastatin group (p = 0.96).
fﬁcacyAs stated above, 71 patients completed the 30-month study.
hey included 32 of the pitavastatin and 39 of the atorvastatin
roup. Table 2 summarizes the percent and absolute changes in
able 1
aseline characteristics of study patients.
All (n = 129) 
Age (years) 68.2 ± 10.1 
Males  105 (81.4%) 
Body  mass index (kg/m2) 24.5 ± 3.24 
Systolic  blood pressure (mmHg) 131 ± 16.7 
Diastolic  blood pressure (mmHg) 74 ± 10.8 
Hypertension 107 (82.9%) 
Diabetes  mellitus 52 (40.3%) 
Current  smoking 39 (30.2%) 
Family  history of CAD 25 (19.4%) 
Old  myocardial infarction 65 (50.4%) 
Percutaneous coronary intervention 110 (85.3%) 
Total  cholesterol 192.1 ± 26.9 
Low-density  lipoprotein cholesterol 122.7 ± 22.5 
High-density lipoprotein cholesterol 39.8 ± 5.9 
Triglyceride  124 (33, 165) 
Adiponectin  9.4 ± 6.4 
Glucose  125.0 ± 50.0 
Hemoglobin  A1c 5.9 (5.5–6.6) 
Statin  49 (38.0%) 
Calcium-blocker 64 (49.6%) 
-Blocker 42  (32.6%)
Angiotensin-converting enzyme inhibitor 44 (34.1%) 
Angiotensin  II receptor blocker 46 (35.7%) 
Insulin  25 (19.4%) 
Sulfonylurea  16 (12.4%) 
-Glucosidase  inhibitor 11 (8.5%) 
Antiplatelet  agents 128 (99.2%) 
Nitrate  29 (22.5%) 
ata are mean ± SD or number of patients (percent). Triglyceride is expressed as mediansiology 62 (2013) 87–94 89
the primary and secondary endpoint parameters (differences in
each variable between baseline and after 30 months of treatment)
between these two groups. With regard to the primary endpoint,
the percent and absolute changes in HDL-C and ApoAI, were signif-
icantly greater in the pitavastatin group than in the atorvastatin
group. On the other hand, there were no signiﬁcant differences
in the effects of pitavastatin and atorvastatin on LDL-C, total-C,
non-HDL, triglyceride, and ApoB at 30 months treatment. During
the study, serum HDL-C levels increased progressively over time
in the pitavastatin group, with an increase of 9.4% (p = 0.71) at 6
months, 15.8% (p = 0.037) at 12 months, and 20.1% (p = 0.013) at 30
months (Figs. 1 and 2). On the other hand, HDL-C level ceased to
increase by 6 months (10.7%) and decreased at 12 months (9.3%)
and 30 months (6.3%) in the atorvastatin group (Figs. 1 and 2).
ApoAI levels increased over time, with increase of 7.9% (p = 0.63) at
6 months, 13.0% (p = 0.035) at 12 months, and 20.8% (p = 0.034) at 30
months in the pitavastatin group, though there were no inter-group
differences, as tested by Bonferroni adjusted p-values at follow-
up points (Figs. 3 and 4). We  found that LDL-C/HDL-C ratio at 30
months treatment was  signiﬁcantly lower in the pitavastatin group
(<1.5) compared to the atorvastatin group and the decreasing per-
cent changes in LDL-C/HDL-C ratio were signiﬁcantly greater in the
pitavastatin group than in the atorvastatin group. ApoB/ApoAI ratio
was also signiﬁcantly decreased after 30 months in both groups
and pitavastatin treatment exhibited signiﬁcantly lower levels of
ApoB/ApoAI ratio compared to atorvastatin treatment at 30 months
(Table 2).
There  were no signiﬁcant inter-group differences between
pitavastatin and atorvastatin groups in terms of total adiponectin,
fasting glucose, and HbA1c. Adiponectin levels progressively
increased over time in the pitavastatin group, but did not change
signiﬁcantly in the atorvastatin group (Fig. 5). In the pitavastatin
group, fasting blood glucose level was  higher at 30 months com-
pared with the baseline, but there were no signiﬁcant changes in
the percent and absolute changes between the two groups. HbA1c
level was  signiﬁcantly higher at 6 months in the atorvastatin group,
Pitavastatin (n = 65) Atorvastatin (n = 64) p-Value
68.4 ± 9.1 68.9 ± 10.2 0.77
53 (81.5%) 52 (81.3%) 0.96
24.3 ± 3.05 24.8 ± 3.41 0.26
131 ± 16.7 132 ± 17.6 0.80
73 ± 10.7 75 ± 11.1 0.34
54 (83.1%) 53 (82.8%) 0.97
27 (41.5%) 25 (39.1%) 0.77
20 (30.8%) 19 (29.7%) 0.95
12 (18.5%) 13 (20.3%) 0.93
33 (50.8%) 32 (50.0%) 0.93
55 (84.6%) 55 (86.0%) 0.86
191.5 ± 25.3 192.6 ± 28.6 0.83
122.6 ± 21.2 122.9 ± 23.9 0.94
39.9 ± 6.5 40.1 ± 5.5 0.90
114 (83, 164) 133 (98, 165) 0.43
9.4 ± 7.1 9.5 ± 5.6 0.96
126.6 ± 59.8 120.4 ± 34.4 0.62
5.9 (5.5–6.6) 5.9 (5.4–6.5) 0.77
25 (38.5%) 24 (37.5%) 0.76
31 (47.7%) 33 (51.6%) 0.66
22 (33.8%) 20 (31.3%) 0.75
22 (33.8%) 22 (34.4%) 0.95
23 (35.4%) 23 (35.9%) 0.95
20 (30.8%) 5 (7.8%) 0.26
9 (13.8%) 7 (10.9%) 0.62
6 (9.2%) 5 (7.8%) 0.77
65 (100%) 63 (98.4%) 0.31
15 (23.1%) 14 (21.9%) 0.87
 with interquartile range. CAD, coronary artery disease.
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Table 2
Changes in laboratory data after 30 months of treatment.
Pitavastatin (n = 32) Atorvastatin (n = 39) p-Value
Baseline 30 months Baseline 30 months
HDL-C 40.66 ± 7.16 47.97 ± 9.67**,† 40.18 ± 5.48 42.44 ± 8.76 –
Absolute  change 4 (1 to 13) 3 (−2 to 7) 0.015
%Change  11.1 (2.2 to 35.3) 8.1 (−5.3 to 16.3) 0.013
Triglyceride  104 (75–131) 103 (69–128) 149 (124–196) 116 (85–191)† –
Absolute  change −13 (−48 to 20) −21 (−49 to 5) 0.62
%Change  −12.8 (−41.6 to 24.1) −15.8 (−32.1 to 25.5) 0.29
Total  cholesterol 189.0 ± 26.5 158.7 ± 21.8** 196.5 ± 30.76 161.9 ± 29.6** –
Absolute  change −29 (−51 to −17) −35 (−59 to −8) 0.59
%Change  −14.9 (−24.3 to −9.1) −12.5 (−26.2 to −3.3) 0.60
LDL-C  121.5 ± 23.6 87.3 ± 21.1** 123.2 ± 25.7 92.3 ± 26.2** –
Absolute  change −32  (−55 to −19) −29 (−45 to −7) 0.64
%Change  −28.7 (−40.8 to −16.8) −25 (−36.4 to −8.4) 0.57
Non-HDL-C  148.4 ± 27.1 71.44 ± 10.1** 156.3 ± 29.7 69.62 ± 12.07** –
Absolute  change −74 (−92 to −62) −87 (−106 to −69) 0.16
%Change  −52.4 (−60 to −43.7) −54.3 (−61.6 to −48.9) 0.12
LDL-C/HDL-C 3.12 ± 1.08 1.20 ± 0.60**,† 3.12 ± 0.74 2.25 ± 0.76** –
Absolute  change −1 (−1.7 to −0.7) −0.7 (−1.4 to −0.4) 0.08
%Change  −38 (−49.9 to −29.2) −30.8 (−39.7 to −14.7) 0.029
ApoAI  115.8 ± 15.82 138.9 ± 23.2**,† 116.7 ± 14.9 128.8 ± 19.2** –
Absolute  change 20 (10–34) 13 (1–24) 0.023
%Change  15.9 (8.3–31.3) 11 (0.8–23.4) 0.034
ApoB  103.2 ± 16.7 82.3 ± 17.0** 107.5 ± 19.1 88.6 ± 21.2** –
Absolute  change −20 (−33 to −13) −18 (−30 to 4) 0.67
%Change  −19.8 (−29.2 to −12.7) −18.1 (−28.7 to −4.6) 0.46
ApoB/ApoAI  0.92 ± 0.25 0.61 ± 0.17**,† 0.93 ± 0.18 0.7 ± 0.2** –
Absolute  change −0.25  (−0.4 to −0.21) −0.22 (−0.36 to −0.07) 0.12
%Change  −32.4 (−43.3 to −24.6) −27.3 (−36.7 to −9.9) 0.053
Adiponectin  10.14 ± 9.82 12.79 ± 10.87* 9.07 ± 5.34 9.74 ± 6.21 –
Absolute  change 1 (−0.2 to 3.8) 0.9 (−0.7 to 2.7) 0.10
%Change  13.4 (−3.6 to 42.6) 12.1 (−10 to 25.8) 0.15
Glucose  112.6 ± 34.7 124.6 ± 36.0* 125.8 ± 40.4 126.4 ± 43.6 –
Absolute  change 6 (−6 to 22) −1 (−17 to 11) 0.22
%Change  6 (−6.5 to 20.8) −0.9 (−12 to 11.6) 0.33
HbA1c  5.8 (5.5–6.7) 5.8 (5.4–6.5) 6.0 (5.6–6.7) 6.1 (5.7–6.8) –
Absolute  change −0.1 (−0.5 to 0.2) 0 (−0.1 to 0.2) 0.83
%Change  −1.7 (−7.1 to 3.6) 0 (−1.9 to 3.0) 0.62
Data are mean ± SD. Triglyceride is expressed as medians with interquartile range. The percent change and absolute change of each parameter is expressed as medians
with interquartile range. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B; HbA1c,
hemoglobin A1c.
* p < 0.05 vs. baseline.
** p < 0.01 vs. baseline.
F
a
m† p < 0.05 between 30 months.
ig. 1. Serum levels of high-density lipoprotein cholesterol (HDL-C) at baseline, and
fter 6, 12, and 30 months of treatment with pitavastatin and atorvastatin. Data are
ean ± SD of the indicated number of patients.Fig. 2. Percent change in high-density lipoprotein cholesterol (HDL-C) levels during
the course of the 30-month study. Data are mean ± SD of the indicated number of
patients.
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Fig. 3. Serum levels of apolipoproteinAI (ApoAI) at baseline, and after 6, 12, and 30
months of treatment with pitavastatin and atorvastatin. Data are mean ± SD of the
indicated number of patients.
Fig. 4. Percent change in apolipoproteinAI (ApoAI) levels during the course of the
30-month study. Data are mean ± SD of the indicated number of patients.
Fig. 5. Serum levels of adiponectin at baseline, and after 6, 12, and 30 months of
treatment with pitavastatin and atorvastatin. Data are mean ± SD of the indicated
number of patients.Fig. 6. Serum levels of hemoglobinA1c (HbA1c) at baseline, and after 6, 12, and 30
months of treatment with pitavastatin and atorvastatin. Data are mean ± SD of the
indicated number of patients.
but no signiﬁcant change was  noted at 30 months (relative
to the baseline), and no signiﬁcant difference was  observed
between the two treatment groups (Fig. 6).
Among the sub-population of patients with HDL-C < 40 mg/dl,
we found 11 patients in the pitavastatin group and 17 in the ator-
vastatin group. We  analyzed changes in serum HDL-C levels in
these patients. The percent and absolute changes in HDL-C were
signiﬁcantly greater in the pitavastatin group compared to the ator-
vastatin group (% HDL-C change: pitavastatin 35.0 [6.4–62.5]% vs.
atorvastatin 11.8 [−5.2 to 18.9]%, p = 0.013; absolute HDL-C change:
pitavastatin 12 [2–19] mg/dl vs. atorvastatin 4 [−2 to 7] mg/dl,
p = 0.018).
In the present study, 103 patients (79.8% of All) were fol-
lowed until 12 months of treatment. Of these 103 patients, we
compared the drug effects between patients who completed the
30-month study (effectiveness population; n = 67) and those who
dropped out before 30 months (dropped out population; n = 36).
In the pitavastatin group, there were no signiﬁcant differences
between the patients included in the effectiveness population and
those in the dropped out population with regard to the primary
end point; the percent and absolute changes in HDL-C (percent
change: 15.2 ± 15.1% vs. 16.6 ± 14.2%, p = 0.75; absolute change:
6.1 ± 6.0 mg/dl vs. 6.3 ± 5.6 mg/dl, p = 0.93). Also in the atorvas-
tatin group, there were no signiﬁcant differences between the
effectiveness population and those in the dropped out population
with regard to the percent and absolute changes in HDL-C (per-
cent change, 9.1 ± 17.5% vs. 9.9 ± 13.2%, p = 0.87; absolute change,
3.2 ± 6.3 mg/dl vs. 3.9 ± 5.4 mg/dl, p = 0.69).
Safety  and tolerability
Adverse  events related to the study drugs occurred in 3 patients
(4.6%) of the pitavastatin group and 2 patients (3.1%) of the atorvas-
tatin group. Adverse events considered to be related to pitavastatin
were skin eruptions (n = 2), and general fatigue (n = 1), while those
considered to be related to atorvastatin were skin eruptions only
(n = 2). There was no signiﬁcant difference in the frequency of
adverse events between the two  groups (p = 0.66). In general,
pitavastatin and atorvastatin were well tolerated. No cardiac event
was registered during the 30-month study period.
In this study, we were able to follow-up 55% of the partici-
pants at 30 months. There were no signiﬁcant differences in the
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aseline characteristics, except for history of old myocardial infarc-
ion between the two groups (efﬁcacy group: 63.4%, drop-out
roup: 34.5%, p = 0.02).
iscussion
In  patients with stable CAD, pitavastatin signiﬁcantly increased
erum levels of HDL-C and this increase was signiﬁcantly larger
han that produced by atorvastatin after 30 months of treatment.
reatment with pitavastatin, but not atorvastatin, signiﬁcantly
ncreased serum levels of adiponectin. We  found pitavastatin
ontinuously increased HDL-C without adverse effects on glu-
ose metabolism in the long-term follow up compared to
torvastatin.
Hypo-HDL-cholesterolemia is an independent risk factor for
therosclerotic cardiovascular events [13]. HDL-C exerts many
iological effects through its anti-atherosclerotic actions. The
ost accepted property of HDL-C is reverse cholesterol transport
RCT), which involves the transfer of excess cholesterol from the
eripheral tissues to the liver [14]. Furthermore, HDL-C exhibits
avorable effects on inﬂammation, LDL-C oxidation, platelet acti-
ation and thrombosis, and restoration of endothelial integrity
hrough the promotion of endothelial nitric oxide (NO) release and
nti-apoptotic effects [15]. Despite strict control of LDL-C using
ipid-lowering agents (statins) for the treatment of dyslipidemia,
he risk of cardiovascular events remained high in patients with
ow serum HDL-C levels in the TNT trial [5]. The present results
howed that pitavastatin increased HDL-C during the 30-month
tudy period, although it signiﬁcantly lowered LDL-C levels sim-
lar to atorvastatin. These effects might be beneﬁcial in preventing
ardiovascular events in patients with CAD for long-term treat-
ent.
The clinical strategies used to increase HDL-C levels are, in
eneral, lifestyle interventions such as weight loss, exercise, ces-
ation of smoking, and moderate alcohol consumption [16]. Statins
re one of the major pharmacotherapeutic options for increasing
DL-C levels. Statins vary in their potency in increasing HDL-C
evel, and have been reported to increase HDL-C by 5–7% [17],
hereas some studies reported reduction in HDL-C level follow-
ng the prolonged use of statins [12,18]. In LIVALO Effectiveness
nd Safety (LIVES) study extension, HDL-C levels increased pro-
ressively over time, with an increase of about 10 mg/dl (28.9%)
fter 5 years of treatment in patients with low HDL-C levels (HDL-
 < 40 mg/dl) [19]. In the present COMPACT-CAD study, patients
ith low HDL-C (HDL-C < 50 mg/dl) showed a progressive increase
n serum HDL-C level over time, with a percent increase of
0.1 ± 25.7% after 30 months of continuous treatment. Our results
upport the results of LIVES study extension. In any treatment
hat focuses on HDL-C, it is important to consider the effect of
he treatment on HDL-C function, in addition to increasing serum
evels of HDL-C. Previous studies demonstrated that inhibition
f cholesterol ester transfer protein (CETP) using torcetrapib did
ot prevent the progression of atherosclerosis and conversely ele-
ated overall mortality, despite the signiﬁcant increase in HDL-C
evels (72.1%) [20]. Statins are thought to increase serum HDL-C
evel through two major mechanisms. One is to produce ApoAI,
hich is considered to increase functional HDL-C particles that
an activate RCT, and the other is to inhibit CETP, which is
hought to produce dysfunctional HDL-C with pro-inﬂammatory
nd atherogenic properties [21]. The available literature sug-
ests that in comparison to atorvastatin, pitavastatin increases
he mRNA levels of ATP-binding cassette transporter A1 (ABCA1),
hich appears to be involved in the control of ApoAI-mediated
holesterol efﬂux [22]. In our study, ApoAI levels increased pro-
ressively during the 30-month period in patients treated withiology 62 (2013) 87–94
pitavastatin  compared to atorvastatin. Considered together, these
results suggest that pitavastatin increases HDL-C levels and could
improve HDL-C function by elevating ApoAI levels and activating
RCT.
A recent meta-analysis study found that treatment with
hydrophilic and lipophilic statins was associated with a slight
increase in the risk of diabetes [23]. In the present study, pitavas-
tatin tended to improve HbA1c levels at 30 months, albeit
insigniﬁcantly, compared with atorvastatin. We  also found treat-
ment with pitavastatin, but not atorvastatin, signiﬁcantly increased
adiponectin levels in the present study. The precise mecha-
nisms of the increase in serum adiponectin levels associated with
pitavastatin treatment remain uncertain. According to one study,
pitavastatin has been reported to activate peroxisome proliferator-
activated receptor (PPAR)  in macrophages [24], suggesting the
possibility that pitavastatin could activate PPAR in the adipose tis-
sue. Pitavastatin also attenuated the development of adipose tissue
inﬂammation [25] and did not impair differentiation/maturation of
preadipocytes and prevented adipocyte hypertrophy in obese mice
(KKAy mice) [26]. These effects of pitavastatin could contribute to
the increase in serum adiponectin levels.
Long-term follow-up of the effects of these medications on glu-
cose metabolism should be determined in future studies.
In  the present study, adiponectin levels progressively increased
over time in the pitavastatin group, but not in the atorvastatin
group, while fasting glucose levels were higher at 30 months
compared with the baseline in the pitavastatin group. We  have
no clear answer to this discrepant result. Fasting glucose levels
were higher at 30 months compared with the baseline, while
HbA1c levels were slightly lower at 30 months from baseline in
the pitavastatin group. These results suggest that mean serum
glucose levels were not elevated and the postprandial glucose
metabolism could not be impaired in the pitavastatin group. On
the other hand, in the atorvastatin group, fasting glucose levels
did not change but HbA1c levels were slightly increased from
baseline. Thus, this result suggested that atorvastatin treatment
might impair the postprandial glucose metabolism compared with
the baseline condition. During the treatment period, pitavastatin,
but not atorvastatin, signiﬁcantly increased adiponectin levels.
We suppose these changes could partly affect the changes in
HbA1c levels. To clarify the precise correlations and mechanisms,
further clinical studies using recently recognized new glucose
metabolism markers such as postprandial glucose, 1, 5-anhydro-
d-glucitol, and continuous glucose-monitoring system, would be
required.
In this 30-month COMPACT-CAD study, pitavastatin treatment
was associated with signiﬁcant increase in serum levels of HDL-
C and ApoAI, compared with atorvastatin in patients with stable
CAD. Pitavastatin increased serum HDL-C levels without adverse
effects on glucose metabolism, compared with atorvastatin. Taken
together, pitavastatin seems to have well-balanced beneﬁcial
effects in patients at high risk for cardiovascular events and
these effects are mediated by reducing LDL and increasing HDL-C
levels.
The present study has certain limitations. Although the study
was prospective in nature, we  were able to obtain blood sam-
ples to examine the endpoint items after 30 months of continuous
treatment from 55% of the participants who registered at study
entry. Because subjects of this clinical study were volunteers with
no incentives for participation, patient motivation over the long
follow-up period proved difﬁcult. In the present study, many
patients unfortunately failed to complete the 30-month follow up
mainly because of withdrawal of consent. But at 12 months from
baseline, both in the pitavastatin and atorvastatin group, we  found
similar therapeutic effects of these two  statins on the primary
end point and other parameters between the patients with the
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ffectiveness population (n = 67) and with the dropped out popula-
ion (n = 36). Based on these results, it could be suggested that high
rop-out rate after 12 months might not strongly affect the main
esults of the present study at 30 months. Further clinical studies of
ong-term follow-up with higher follow-up rate are required to
onﬁrm our results.
Regarding  the entry criteria, deﬁnition of hypo-HDL-
holesterolemia was serum HDL-C concentration < 50 mg/dl
n this study. In a post hoc analysis of the TNT trial which was
onducted in patients with CAD taking 10 mg of atorvastatin,
he risk of cardiovascular events was signiﬁcantly reduced in
hose with serum HDL-C ≥ 55 mg/dl [5]. And in the whole study
opulation of the TNT study, serum HDL-C ≥ 43 mg/dl was  sig-
iﬁcantly associated with a decrease in cardiovascular events.
urthermore, in the Japan Lipid Intervention Trial (J-LIT), the inci-
ence of coronary events was signiﬁcantly lower in patients with
erum HDL-C ≥ 50 mg/dl [27]. Based on these facts, we  applied the
ssential entry criteria as serum HDL-C < 50 mg/dl in this study.
lthough similar results were observed in the subpopulation
f patients with HDL-C < 40 mg/dl in the present study, further
tudies with a large number of patients are needed to conﬁrm our
esults in CAD patients with hypo-HDL-cholesterolemia deﬁned as
DL-C < 40 mg/dl.
onclusion
In  patients with stable CAD, hyper-LDL-cholesterolemia, and
ypo-HDL-cholesterolemia, 30-month treatment with pitavastatin
as associated with signiﬁcantly greater increases in serum HDL-C
nd ApoAI than atorvastatin.
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